Pharmaceutical - Johnson & Johnson, Stelara Injection

Filter

Popular Filters

Modest growth forecast for global Crohn’s disease market

Modest growth forecast for global Crohn’s disease market

04-02-2014

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2…

AbbVieBiotechnologyEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeStelara InjectionTakeda Pharmaceuticals

UK’s NICE draft guidance negative on Stelara for psoriatic arthritis

UK’s NICE draft guidance negative on Stelara for psoriatic arthritis

27-12-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has opened a consultation…

Anti-Arthritics/RheumaticsEuropeJanssenJohnson & JohnsonPharmaceuticalPricingRegulationStelara InjectionUK

Sales of psoriasis drugs to be worth $7.4 billion by 2020

19-04-2013

The psoriasis market experienced approximately 36.5 million prevalent cases across the USA, France, Germany,…

AbbVieAmgenAsia-PacificDermatologicalsEnbrelEuropeHumiraJohnson & JohnsonMarkets & MarketingNorth AmericaNovartisPfizerPharmaceuticalsecukinumabStelara Injectiontofacitinib

Janssen files Stelara for active psoriatic arthritis in USA and EU

07-12-2012

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen yesterday submitted a supplemental…

Anti-Arthritics/RheumaticsBiotechnologyEuropeJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationStelara Injection

Highlights of ACR meeting include new Cimzia, Stelara and Simponi data

13-11-2012

Belgian drugmaker UCB (UCB: BR) presented results for Cimzia (certolizumab pegol), from the Phase III…

Anti-Arthritics/RheumaticsCimziaJohnson & JohnsonPharmaceuticalResearchSimponi InjectionStelara InjectionUCB

Study finds potential use of ustekinumab for Crohn's disease

18-10-2012

Ustekinumab, an antibody proven to treat the skin condition psoriasis, has now shown positive results…

BiotechnologyGastro-intestinalsJanssenJohnson & JohnsonPharmaceuticalResearchStelara Injectionustekinumab

More news at EULAR from Novartis, J&S and B-MS

07-06-2012

Highlights presented at the annual congress of the European League Against Rheumatism (EULAR 2012), in…

Anti-Arthritics/RheumaticsBristol-Myers SquibbIlarisJohnson & JohnsonNovartisOrenciaPharmaceuticalResearchSimponi InjectionStelara Injection

Parexel

Parexel

Back to top